Authors
Latest:
Dr. Hellmann on the Impact of Systemic Therapy on Surgery in Ovarian CancerMira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.
Latest:
Neural "Fingerprint" Enables Personalized SBRT Dose for Lung CancerA prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.
Latest:
Dr. Haigentz on the Importance of Adjuvant Osimertinib in EGFR+ NSCLCMissak Haigentz Jr., MD, discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.
Latest:
Dr. Hoffman on Research Regarding Neoadjuvant Chemo and Primary Debulking in Ovarian CancerMitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.
Latest:
Dr. Benson on Extensive Biopsies for Low-Risk Prostate CancerMitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses extensive biopsies in low-risk patients with prostate cancer.
Latest:
Molecular Signature Distinguishes Indolent From Aggressive Prostate CancerProstate cancer is one of the most common forms of cancer in older men, with more than 200,000 new diagnoses per year.
Latest:
Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCLMitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.
Latest:
Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion–Positive CholangiocarcinomaMitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.
Latest:
Dr. Mirza on Hematuria and a Bladder Cancer DiagnosisMoben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.
Latest:
Neural "Fingerprint" Enables Personalized SBRT Dose for Lung CancerA prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.
Latest:
Battling Burnout: Advice On Preventing and Dealing with Burnout in Your Future CareerA career in oncology can be a tremendously fulfilling and a meaningful venture. Oncologists care for the sick, advance medical science, and mentor the next generation of medical professionals.
Latest:
Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case ReportThis is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Latest:
Cleveland Clinic Researchers Explore Genetic Landscape of Radiotherapeutic ResistancePriyanka Gopal, MD, and Mohamed E. Abazeed, MD, PhD, discuss radiotherapy in the era of precision medicine.
Latest:
Dr. Salem on the Results of the MyPathway Trial in mCRCMohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).
Latest:
Dr. Jahanzeb on Immunotherapy in Oncogene-Driven NSCLCMohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, at University of Miami Miller School of Medicine, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer.
Latest:
Dr. Abdul Hay on Evaluation of Transplant Eligibility in ALLMohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.
Latest:
Dr. Abdul-Hay on the Use of HCT-CI to Guide Transplant Eligibility in ALLMohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).
Latest:
Achieving Career Success in Academic OncologyAcademic oncologists have a critical role as opinion leaders and shape the future of cancer care by research and training future oncologists, residents, and medical students.
Latest:
Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCCMohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.
Latest:
Dr. Rahman on Understanding the Role of Biosimilars in OncologyMohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses his understanding of the role of biosimilars in oncology.
Latest:
Ongoing Research in GI CancersMohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Latest:
Dr. Rahman on Pertuzumab and Neratinib in HER2+ Breast CancerMohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses the roles of pertuzumab and neratinib in patients with HER2-positive breast cancer.
Latest:
MSK Pioneers Interventional Pulmonology Techniques in Lung Cancer FieldAdvanced interventional pulmonology techniques are revolutionizing the diagnosis and treatment of lung cancer.
Latest:
Dr. Siddiqui on Likely Candidates to Develop Prostate CancerMohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.
Latest:
Dr. Arnedos on Next Steps Following the POP Randomized Trial in Breast CancerMonica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, shares some of her thoughts regarding next steps following the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.
